CraniUS Therapeutics

Executive Summary

CraniUS Therapeutics is a Boston-based medical device company developing NeuroPASS™, a skull-implanted drug delivery system designed to bypass the blood-brain barrier (BBB) for direct, targeted treatment of brain diseases. Founded in 2020, the company aims to address the significant challenge of delivering therapeutics to the central nervous system, which is often limited by systemic side effects and poor brain penetration. NeuroPASS™ could enable more precise dosing, reduce toxicity, and transform treatment paradigms for conditions such as glioblastoma, Alzheimer's, and Parkinson's disease. While the technology is novel and potentially disruptive, it remains early-stage with limited publicly available clinical data. The company's 'Approved' stage designation suggests regulatory clearance for clinical evaluation, but commercialization and broad adoption still face technical, regulatory, and competitive hurdles.

Upcoming Catalysts (preview)

• Q3 2026First-in-human clinical trial initiation for NeuroPASS™70% success
• Q1 2027Strategic partnership or licensing agreement for CNS drug delivery55% success
• Q4 2026FDA investigational device exemption (IDE) approval for pivotal study60% success